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Abstract
Previous studies in our laboratory have shown that
the elevation of reactive oxygen species levels and the
repression of the antioxidant enzyme, catalase, played
a critical role in the in vitro progression of benign
papilloma cells to malignant carcinoma cells. Catalase
message, protein levels, and activity levels were found
to be downregulated in the malignantly progressed
cells. The goal of this study is to further characterize
the repression of catalase in malignant progression of
mouse skin tumors. To validate the in vitro observa-
tions, we examined catalase expression in tumor
samples generated by the multistep chemical carcino-
genesis protocol. Higher levels of catalase mRNA and
protein were observed in benign papillomas versus
malignant carcinomas. Nuclear run-on analysis show-
ed that catalase repression in the cultured malignant
cells was transcription-dependent. Results from luci-
ferase reporter assays indicated that malignant cells
have lower catalase promoter activities than benign
papilloma cells, in part through the Wilm’s tumor
suppressor 1 (WT1) binding site within the proximal
promoter region. The WT1 protein levels were found
to be inversely correlated with the observed catalase
promoter activities, with higher levels observed in
the malignant cells versus the benign cells. These re-
sults led us to conclude that WT1 is acting as a tran-
scription repressor in catalase gene regulation during
tumor progression.
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Introduction
Nonmelanoma skin cancer is the most common form of
malignancy in the United States. It is estimated that over
1 million new cases are diagnosed every year [1]. About
20% of those cases are categorized as squamous cell car-
cinomas (SCCs) [2]. The multistep mouse skin carcinogen-
esis protocol has provided researchers a model system to
study and identify key events in the development of such
cancers. The protocol is divided into three major steps,
including initiation, promotion, and progression [3]. Initiation
involves the application of a carcinogen such as 7,12- dime-
thylbenzanthracene (DMBA) to normal mouse skin to induce
genetic mutations in the epidermal cells. In the promotion step,
a tumor promoter such as 12-O-tetradecanoyl-phorbol-13-
acetate (TPA) is applied to cause a selective outgrowth of
initiated cells that carry activating Ha-ras gene mutations [4].
The hyperproliferation of these cells leads to the development
of benign papillomas. In the progression step, additional ge-
netic and epigenetic changes are acquired by the tumor cells
to convert from benign papillomas to malignant SCCs. In a
previous study, we developed an in vitro model to study the
molecular mechanisms involved in the malignant progression
process [5]. The benign papilloma-producing mouse keratino-
cyte cell line 308, containing a Ha-ras mutation [6], was
subjected to repeated treatments with N-methyl-NV-nitro-N-
nitrosoguanidine (MNNG) or ionizing radiation to introduce
DNA damage, thus enhancing their conversion into malignant
cells. This protocol produced two malignantly transformed cell
lines: 6M90 (for-MNNG treated) and 6R90 (for ionizing radia-
tion–treated). The 6M90 and 6R90 cells were able to develop
into SCCs upon subcutaneous injection into athymic nude
mice. In comparison, the parental 308 cells were unable to form
tumors when injected subcutaneously. We reported previously
that the malignant variants had elevated levels of steady-state
reactive oxygen species (ROS) in comparison to the parental
308 cells, and this elevation of ROS played a functional role in
maintaining the malignant phenotypes of the 6M90 and 6R90
cells [5].
ROS, which include superoxide anion, hydroxyl radical,
hydrogen peroxide, and singlet oxygen, are continuously pro-
duced by the cell in a variety of normal cellular functions. The
majority of ROS are generated by the mitochondria as un-
wanted by-products during cellular respiration. The cell em-
ploys a host of antioxidant defense mechanisms to maintain
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the steady-state level of ROS. In a previous study, we
showed that attenuation of the antioxidant defense enzyme,
catalase, was mainly responsible for the elevated ROS
levels found in our malignantly transformed cell lines [7].
We showed that catalase message, protein levels, and
activity levels, in both 6M90 and 6R90 cells, were decreased
compared to the parent 308 cells. The catalase activities in
the malignant cell lines were found to decrease from 21.5 ±
1.63 mmol/min per milligram of protein in 308 cells to 10.96 ±
1.73 and 7.23 ± 0.57 mmol/min per milligram of protein in
6M90 and 6R90 cells, respectively. We were unable to detect
any significant changes in the expression and activity levels
of Mn or Cu/Zn superoxide dismutase in the malignant cells.
The levels of glutathione (both oxidized and reduced form)
were decreased in 6M90 and increased in 6R90 compared
to the 308 cells [7]. These data indicated to us that the
changes in glutathione might not be as critical or common as
the repression of catalase in the progression of cancer cells.
In addition, expression of an exogenous rat catalase gene
in the 6M90 and 6R90 cells resulted in an increase in cat-
alase activities and a reduction of ROS [8]. Taken together,
these observations demonstrated that downregulation of
catalase expression plays a crucial role in the elevation of
ROS in the malignantly transformed 6M90 and 6R90 cells.
Catalase is a heme-containing enzyme found mainly in
the peroxisomes and cytosol, and is responsible for detox-
ifying hydrogen peroxide by catalyzing its degradation to
water and oxygen. We hypothesized that catalase functions
as a tumor-suppressor gene in the malignant progression
of mouse skin tumors. Repression of catalase causes the
elevation of hydrogen peroxide, which acts as a secondary
messenger to activate signal transduction pathways, leading
to the formation of SCC. Our goal in this study was to deter-
mine the mechanism(s) behind catalase repression during
tumor progression.
Materials and Methods
In Vivo Tumor Progression
A single initiating dose of 100 mg of DMBA (Sigma, St.
Louis, MO) in 0.2 ml of acetone was applied topically to the
shaved backs of female ICR mice (Harlan Sprague Dawley,
Indianapolis, IN). It was followed by twice-weekly application
of 5 nmol of TPA (Alexis Corp., San Diego, CA) in 0.2 ml of
acetone for 21 weeks. On week 22, TPA applications were
stopped and replaced with weekly application of 120 mg of
MNNG in 0.2 ml of acetone for a total of 40 weeks.
Histology and Immunohistochemistry
Formalin-fixed and paraffin-embedded tumor samples
were cut into 5-mm serial sections. The sections were hema-
toxylin and eosin (H&E)–stained and used for pathology to
determine tumor classifications. Immunohistostainings were
performed on the remaining sections. Briefly, the sections
were deparaffinized with xylene and rehydrated with ethanol.
The sections were rinsed in PBS and incubated with the
following primary antibodies: catalase (Rockland, Gilberts-
ville, PA), keratin 1, and keratin 10 (Berkeley Antibody
Company, Richmond, CA). The pan-keratin antibody, 18A,
was given by Dr. Raymond Nagle (Department of Pathology,
University of Arizona, Tuczon, AZ) and had been shown to
stain high-molecular-weight cytokeratins from the epidermis.
The Vectastain ABC kit (Vector Laboratories, Burlingame,
CA) was used to perform the secondary antibody incuba-
tions. The staining was visualized with diaminobenzidene
(DAB) and counterstained with hematoxylin.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR) Assay
Total RNA were isolated from the cultured cells or frozen
tumor sample using the RNeasy Mini Kit (Qiagen, Chats-
worth, CA) and quantitated by spectrophotometry. Two hun-
dred nanograms of total RNA was used to generate random
hexamer primed cDNA with the Omniscript Reverse Tran-
scription kit (Qiagen). Ten percent of the cDNA product was
used to perform real-time PCR for the quantitation of
the catalase and GAPDH message levels. The primers and
Taqman probes for the assay were purchased from the
Assay-by Design Service (Applied Biosystems, Foster City,
CA). The sequences of the primers and probe used for
detecting the catalase message were as follows: mCas1
forward primer (5V-CCGACCAGGGCATCAAAA-3V), mCas1
reverse primer (5V-GAGGCCATAATCCGGATCTTC-3V), and
mCas1 probe (5V-6FAM-CAGGAAGGCTTGCTC-3V). The
sequences of the primers and probe used for detecting
GAPDH message were as follows: mGAPDH forward primer
(5V-GTCCTGAGTATGTCGTGGAGTCTAC-3V), mGAPDH
reverse primer (5V-GGCCCCGGCCTTCTC-3V), and
mGAPDH probe (5V-6FAM-ATGGTGGTGAAGACAC-3V).
The real-time PCR assay was carried out with the Taqman
Universal PCR Master Mix and the ABI PRISM 7700 Se-
quence Detection System (Applied Biosystems) under the
follow conditions: 50jC for 2 minutes, 95jC for 10 minutes,
followed by 40 cycles of 95jC for 15 seconds, 60jC for 1
minute. The Relative CT Method (described in the User
Bulletin No. 2, ABI PRISM 7700 Sequence Detection Sys-
tem, pp. 11–15) was used to calculate the relative mRNA
level of catalase (normalized to GAPDH) in each sample.
Cells and Cell Culture
Papilloma-derived mouse skin keratinocyte 308 cells
were kindly provided by Dr. Stuart H. Yuspa [6]. The pro-
gressed variants, 6M90 and 6R90 cells, were generated as
described in previous publications [5,7]. The cells were
cultured in minimal essential medium (Invitrogen, Carlsbad,
CA) supplemented with 7.5% fetal bovine serum, 2.5% calf
serum (Gemini Bioproducts, Woodland, CA), 500 U/ml pen-
icillin, and 5000 U/ml streptomycin (Invitrogen) at 37jC in
a 7% CO2 humidified environment.
Southern Blot Analysis
Genomic DNA was isolated from the cultured cells as
previously described [9] and quantitated by spectropho-
tometry. The DNA was digested overnight with 10 U/mg
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restriction enzymes (New England Biolaboratories, Beverly,
MA) at 37jC. Twenty-five micrograms of digested DNA was
eletrophoresed on a 1% agarose gel and transferred onto
a GeneScreen membrane (NEN Life Science Products,
Boston, MA) with the Pressure Blotter (Stratagene, La Jolla,
CA). The membrane was hybridized with 32P-labeled cDNA
probes according to the manufacturer’s protocol. The hybrid-
ized bands were visualized and quantitated with the MD
Storm Phosphorimaging system (Molecular Dynamics, Sun-
nyvale, CA).
Catalase Promoter Sequencing
Genomic DNA was isolated as described above for
Southern blot analysis. The DNA was subjected to two
rounds of PCR with nested primers for amplification. The
outside flanking primers for the first round of PCR are as
follows: 567 to 546 (5V-CCTCTCCCCACAAACAAA-
GAGC-3V) and +110 to +93 (5V-GCTGGGTCCCGACT-
GTCC-3V). The internal nested primers for the second
round of PCR are as follows: 557 to530 (5V-CAAACAAA-
GAGCTTTTCAGTATTCTTCC-3V) and +89 to +70 (5V-
ATGGTGTAGGATTGCGGAGC-3V). The PCR reaction was
performed with the Pfx polymerase (Invitrogen) to increase
the fidelity of the product. PCR was performed under the
follow conditions: 94jC for 3 minutes followed by 25 cycles
of 94jC for 1 minute, 58jC for 1 minute, and 68jC for 1.5
minutes, ending with a final extension at 68jC for 5 minutes.
The PCR product was diluted 1:300 to be used as template
for the second round of PCR, which was performed under
identical conditions. The 646-bp product after two rounds of
PCR was cloned into pCR 2.1 and sequenced as described
for bisulfite sequencing.
Nuclear Run-On
A novel nonradioactive-based nuclear run-on method [10]
was used in conjunction with real-time RT-PCR to assay for
catalase transcription rate in our cell lines. Briefly, 50  106
cells were trypsinized and washed twice in Ca2+- and Mg2+-
free PBS. The cell pellet was resuspended in cell lysis buffer
containing 10 mM Tris–HCl, pH 7.4, 3 mM MgCl2, 10 mM
NaCl, 150 mM sucrose, and 0.5% NP-40. The nuclei were
collected by centrifugation and stored frozen in 40% glycerol
at 70jC until used. The run-on reaction was carried out in
a 2  transcription buffer containing 200 mM KCl; 20 mM
Tris–HCl, pH 8.0; 5 mM MgCl2; 5 mM dithiothreitol (DTT);
4 mM each of ATP, GTP, and CTP; 200 mM sucrose; and
20% glycerol. The reaction was initiated with the addition of
4 mM biotin-16-UTP (Roche Applied Science, Indianapolis,
IN) and incubated for 1 hour at 29jC. The RNA was isolated
with Trizol reagent (Invitrogen) according to the manufactur-
er’s protocol. Dynabeads M-280 (Dynal, Oslo, Norway), a
magnetic bead covalently linked to streptavidin, was used
to isolate the biotin-labeled run-on RNA according to the
manufacturer’s protocol. The beads were resuspended in
RNase-free water and stored at 20jC until used. Reverse
transcription and real-time PCR were performed as de-
scribed above.
Sodium Bisulfite Genomic Sequencing
Genomic DNA was isolated as described above for
Southern blot analysis. Five micrograms of DNA was mod-
ified with sodium bisulfite under the conditions described
[11]. Briefly, DNA was denatured with 0.3 M NaOH and treat-
ed with sodium bisulfite at 55jC for 14 hours. The DNA were
desalted by the Wizard Prep kit (Promega, Madison, WI) and
desulfonated with 0.3 M NaOH. The DNA was then puri-
fied with standard ethanol precipitation and subjected to
two rounds of PCR with nested primers for amplification.
The nested primers were designed specifically to the bisul-
fite-modified DNA sequence for the mouse catalase promot-
er region. The outside flanking primers for the first round
of PCR are as follows: 527 to 507 (5V-GGGAGAAAATG-
GAGGAGTTTG-3V) and +140 to +119 to (5V-CTACTCCTTC-
CACTACTTCATC-3V). The internal nested primers for the
second round of PCR are as follows: 268 to 248 (5V-GA-
GGAATTGGATTTTGAGTTG-3V) and +112 to +92 (5V-CTA-
ACTAAATCCCAACTATCC-3V). PCR was performed under
the following conditions: 95jC for 1 minute followed by
35 cycles of 92jC for 1 minute, 55jC for 3 minutes, and
72jC for 1 minute, ending with a final extension at 72jC for
5 minutes. Twenty percent of the PCR product was used as
the template for the second round of nested PCR. Identical
conditions were used for the second round of PCR. After two
rounds of amplifications, the PCR product was subjected to
1% agarose gel electrophoresis for separation. The 380-bp
product was excised from the gel and purified with the
Qiaex II kit (Qiagen). The purified product was cloned into
the pCR 2.1 TA cloning vector according to the protocol
provided by Invitrogen. Ten positive recombinant clones
were isolated from each cell line using the QIAprep Spin
Plasmid Miniprep kit (Qiagen) and sequenced by an ABI
automated DNA sequencer (University of Arizona Sequenc-
ing Facility). The methylation status of CpG islands on the
catalase promoter was determined by comparing the bisul-
fite-modified sequence to the published GeneBank se-
quence (accession no. L25070).
Transient Transfection and Luciferase Assay
The series of catalase promoter luciferase reporter con-
structs was a kind gift from Dr. Thomas A. Rando (Stanford
University) [12]. About 1.5  105 cells were plated into six-
well plates the day before the experiment. They were
transiently transfected with 0.5 mg of plasmid DNA using
the DOTAP liposomal transfection reagent (Avanti Polar
Lipids, Alabaster, AL) for 12 hours. The transfectant was
then removed and the cells were left to recover for an
additional 12 hours in full serum-containing medium before
harvesting. The cells were harvested in Cell Culture Lysis
Reagent (Promega). The protein concentrations of the
samples were determined by the DC protein assay (Bio-
Rad Laboratories, Hercules, CA). Five micrograms of pro-
tein was used for each reaction. The luciferase activity was
measured with the single luciferase kit (Promega) on a TD-
20/20 luminometer (Turner Designs, Sunnydale, CA). The
relative activity was calculated by dividing the raw light units
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of each sample by the raw light units of control samples
that had been transfected with pGL3 control plasmid
(Promega).
Site-Directed Mutagenesis of Wilm’s Tumor Suppressor
(WT1) Consensus Binding Site
The QuikChange II Site-Directed Mutagenesis Kit from
Stratagene was used in accordance with the manufactur-
er’s protocol. The following mutational primers were used:
5 V- GGCGGCCGTCCCAAGTTATGGGGGCGG -
TGCTGATTG-3V and 5V-CAATCAGCACCGCCCCCATAA-
CTTGGGACGGCCGCC-3V. The underlined bases represent
the WT1 binding site that was mutated in the 191/+68
construct.
Results
Catalase Expression In Vivo
We have shown that catalase expression was attenuated
in the in vitro progression model [7]. To validate that
observation, we decided to examine catalase expression
in tumors generated in vivo. A multistep chemical carcino-
genesis protocol with DMBA (initiating agent) and TPA
(promoting agent) was used to generate papillomas on
the mouse skin [3]. A third stage carcinogen, MNNG, was
applied to increase the rate of conversion into SCCs. A
total of 12 tumors was harvested and examined for catalase
expression. The tumors were classified into six papillomas
and six SCCs based on gross anatomy. Immunostaining
was used to detect the expression of catalase on the
formalin-fixed tumor sections. Detailed histologic examina-
tion on H&E–stained sections revealed that most tumors
were heterogeneous in their pathology. At the end of
experiment, most of the ‘‘papillomas’’ have started the
progression process and contained small areas that were
classified as SCCs. However, most ‘‘carcinomas’’ retained
small areas that have not undergone the progression pro-
cess and those sections were classified as papillomas in
nature. As a result, we performed additional immunostaining
with keratinocyte differentiation markers, keratins 1 and 10,
to confirm with the pathology of particular sections. Keratins
1 and 10 are known to be highly expressed in well-differen-
tiated keratinocytes found in normal skin and papillomas,
but lost in dedifferentiated SCCs [13]. High catalase expres-
sion was detected in all the well-differentiated papilloma
sections examined (Figure 1A). Conversely, very low to no
catalase expression was detected in the dedifferentiated
carcinoma sections examined (Figure 1E). In addition, we
wanted to determine if the loss of catalase expression
correlates to a decrease in catalase mRNA level in the
tumors. Real-time RT-PCR analysis was performed with
RNA isolated from the tumor samples. The average cata-
lase message levels of five papillomas and six SCCs are
shown in Figure 2. The results indicated that carcinomas
have reduced catalase message and protein expression
compared to papillomas.
No Gross Deletion or Rearrangement of the Catalase Gene
Was Detected
We previously observed that malignant variants of 6M90
and 6R90 cells had decreased catalase expression com-
pared to the benign 308 cells [7]. One possibility was that
chemical (MNNG) and physical (g-ray irradiation) mutagens
used to create the malignant phenotypes had caused muta-
tions in the catalase gene. Any deletions and/or rearrange-
ments of the catalase genomic sequence could affect the
expression levels. Southern blot analysis was performed to
detect any gross changes that might have occurred. Ge-
nomic DNA from 308, 6M90, and 6R90 cells were digested
with four unique restriction enzymes and eletrophoresed on a
1% agarose gel. The blot was probed with a 1.8-kb full-length
rat catalase cDNA probe (the coding sequences of rat and
mouse catalase gene are 93% identical) to provide a com-
plete coverage of the catalase gene. As shown in Figure 3,
banding patterns created by all four restriction enzymes were
identical between the three cell lines. These results indicated
that no deletions or rearrangements had taken place in
genomic sequence encoding for the catalase mRNA tran-
script and suggested that an alternate mechanism(s) was
responsible for the decreased expression in the 6M90 and
6R90 cells.
Catalase Message Stabilities Were Not Reduced in the
Malignant Variants
Steady-state message levels represent a balance be-
tween the rate of transcription and the rate of degradation.
Studies in different cell types have shown that catalase
expression can be regulated at the level of message stability
[14,15]. To address the question of whether our malignant
cell lines had decreased catalase message stability, we
performed a time course experiment to measure the mes-
sage half-life of catalase in our three cell lines. We treated
the cells with 1 mg/ml actinomycin D to block transcription and
harvested cellular RNA at time points indicated on Figure 4.
Real-time RT-PCR was used to measure the degradation in
catalase message level after transcription blockage. We did
not find any decrease in message stability in the 6M90 and
6R90 cells compared to the parent 308 cells. In fact, the
6M90 and 6R90 cells’ catalase mRNA appeared to have a
longer half life (t1/2 6M90f51 hours and t1/2 6R90f91 hours)
than the 308 cells (t1/2 308 f17 hours).
Reduced Catalase Transcription Rates in Both 6M90 and
6R90 Cells
There is evidence in the literature to suggest that catalase
expression can be regulated at the transcription level [16,17].
Here, we used nuclear run-on analysis to determine if
decreases in steady-state catalase message levels found
in the malignant variants were due to a lower transcription
rate. Nuclei isolated from 308, 6M90, and 6R90 cells were
incubated with biotin-16-UTP for the run-on reaction. The
newly synthesized biotin-labeled RNA transcripts were cap-
tured by streptavidin-coated magnetic beads. The RNA-
bound beads were used for real-time RT-PCR to evaluate
differences in catalase transcription between cell lines. The
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results showed that malignant variants 6M90 and 6R90 cells
have approximately a 50% decrease in catalase transcription
rates compared to the benign 308 cells (Figure 5). This
suggested that downregulation of catalase expression ob-
served in our in vitro progression model was due to tran-
scriptional depression.
Catalase Promoter Analysis
To determine if there were genetic changes associated
with transcriptional repression, we sequenced the 557 to
+89 region of the catalase promoter in the three cell lines.
Ten individual recombinant clones from each cell lines were
analyzed. We detected a single nucleotide polymorphism
(SNP) in all three cell lines when compared to the published
sequence submitted by Reimer et al. [18]. However, we failed
to detect any sequence differences between the benign 308
and the malignant 6M90 and 6R90 cells. Next, we examined
epigenetic alterations that might have occurred in the malig-
nant progression process. Aberrant cytosine methylation of
a tumor-suppressor gene promoter is a mechanism by
which tumor cells can downregulate its transcription
[19,20]. Sun et al. [21] have shown, by methylation-sensitive
Southern blot analysis, that catalase depression in trans-
formed mouse liver cells was due, in part, to an increase
in cytosine methylation. The mouse catalase promoter se-
quence published by Reimer et al. [18] showed 21 potential
methylation-sensitive CpG sites, making it a likely candidate
as a CpG island that could be targeted for gene regulation.
We performed bisulfite sequencing to examine the methyl-
ation status of 17 individual CpG sites on the 248 to +92
region of the catalase promoter. None of the cytosines in the
catalase promoter of 308, 6M90, and 6R90 cells was found
to be methylated (Table 1). This led us to conclude that
methylation did not play a role in the repression of catalase
in our system.
Catalase Promoter Transactivation
The results from the promoter analysis suggested that the
same catalase promoter might have different transactivation
activities depending on the cell lines. To test this idea, we
employed a series of luciferase reporter constructs driven
by different lengths of the 5V-flanking region of the mouse
catalase gene [2]. The reporter constructs were transiently
transfected into 308, 6M90, and 6R90 cells to assay for
catalase promoter transactivation. The luciferase activities of
308 cells were higher than for 6M90 and 6R90 cells, using all
the fragments tested, from 2621/+68 to 191/+68 (Figure
6A). This indicates that the same catalase promoter has a
higher transactivation potential in 308 cells than its malignant
counterparts 6M90 and 6R90 cells. The deletion series also
allowed us to identify potential regulatory elements that could
explain the repression of promoter activities in the 6M90 and
Figure 1. Catalase, keratin 1, and keratin 10 expression patterns in benign papillomas and SCCs. Tumors were excised from mice and fixed in 10% formalin. The
samples were paraffin-embedded, sectioned, and mounted on glass slides. Immunohistochemistry was performed with anti –bovine catalase (A and E), anti –
mouse keratin 10 (B and F), and anti –mouse keratin 1 (C and G) antibodies at 1:500 dilutions. The Vectastain ABC kit at 1:200 dilution was used to perform the
secondary antibody incubations. Catalase, keratin 10, and keratin 1 stainings were visualized with 5-, 2 1/2– , and 2 1/2–minute incubation of DAB, respectively
(brown staining). Hematoxylin was used to counterstain the nucleus. The pan-keratin antibody specific for high-molecular-weight epidermal cytokeratins (D and H)
was used as a positive control for staining in the samples. (I) Western blot analysis for catalase expression in tumor samples. Lysate from the 308 keratinocyte cell
line was included as a positive control.
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6R90 cells. For all three cell lines, there was a gradual
decrease in luciferase activities from the full-length 2621
to 1994, indicating the presence of positive regulatory
elements that were removed as the fragment was shortened.
A dramatic increase in luciferase activity was then observed
in the next shorter fragment (1694/+68), indicating the
presence of a strong negative regulatory element(s) in
the 300-bp sequence between 1994/+68 and 1694/+68.
The constructs with fragments from 1694/+68 to 191/+68
show similar luciferase activities, indicating a lack of major
regulatory element in those regions. The most significant
finding was the fact that the shortest fragment (191/+68)
retains the repression of catalase promoter transactivation in
the 6M90 and 6R90 cells. These results suggested that a
regulatory element(s) that is responsible for transcriptional
repression resides within the 191/+68 sequence of the
catalase promoter.
Sequence analysis revealed multiple regulatory elements
within the 191/+68 region. They include NF-nB, CAAT
boxes, and GC boxes [12]. Nenoi et al. had reported that
GC box binding proteins play a critical role in the repression
of catalase transcription. The positive transcription regulator,
stimulating protein 1 (SP1), and the negative transcription
regulator, WT1, compete for the GC box binding site within
the human catalase gene promoter to differentially regulate
transcription in leukemia cells [19]. Western blot analysis of
total cellular extracts from our three cell lines showed that the
WT1 protein was expressed at higher levels in the malignant
cells. Densitometry of the WT1 band normalized to b-actin
loading control band revealed an 84% increase in 6M90 and
a 23% increase in 6R90 compared to 308 cells (Figure 6B).
We hypothesized that the increased expression of WT1
protein, a negative transcription regulator, in the malignant
cell lines could lead to the repression of catalase promoter
activity. To test this hypothesis, we performed site-directed
mutagenesis to mutate the WT1 consensus binding site
within theGC box, while retaining the SP1 consensus binding
site in the 191/+68 reporter construct. Luciferase activity of
Figure 2. Depression of catalase mRNA levels in SCCs. Total RNA was
isolated from 12 tumors at the end of the 40-week experiment. The tumors
were divided into six papillomas and six carcinomas based on gross
pathology. Real-time RT-PCR was performed to determine the relative level
of catalase mRNA in each tumor. The relative level of GAPDH mRNA in each
tumor sample was used as an internal standard to normalize loading for the
real-time RT-PCR reaction. The error bars represent ± SEM deviation within
the each sample group (*P < .05 compared to the papilloma group).
Figure 3. Southern blot analysis of catalase genomic structures in 308,
6M90, and 6R90 cells. Twenty-five micrograms of genomic DNA was digest-
ed with the appropriate restriction enzyme overnight and loaded onto a 1%
agarose gel for Southern blotting. The blot was hybridized with a 32P-labeled
rat catalase cDNA probe.
Figure 4. Catalase message stabilities in 308, 6M90, and 6R90 cells. The
cells were treated with 1 g/ml actinomycin D in serum-free medium at
time zero. RNA was isolated at the time points indicated and analyzed with
real-time RT-PCR. To compare the differences between cell lines, catalase
mRNA levels of 308 cells at the zero time point were set to one.
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the WT1 mutated construct was significantly higher than the
wild type, indicating that WT1 protein maybe acting as a tran-
scription repressor in this system (Figure 6C). Moreover, the
mutation causes the luciferase activities of both 6M90 and
6R90 to increase to a level similar to the 308 levels, demon-
strating that WT1 binding site plays a significant role in the
repression of catalase transcription in 6M90 and 6R90 cells.
Discussion
Based on our previous in vitro observations concerning
catalase repression, we hypothesized that catalase func-
tions as a tumor-suppressor gene to impede malignant
transformation of mouse skin tumors. In these studies, we
presented in vivo evidence to support the role of catalase
repression in tumor progression. We showed by immunohis-
tochemistry that papilloma samples have a robust catalase
expression, whereas the SCCs have low to undetectable
levels of catalase expression. We also showed that catalase
mRNA levels correlate with the levels of protein expression in
tumors. We believed that the variations in message levels
(Figure 2) were due to the heterogeneous nature of these
tumors. Total RNA was harvested from frozen tumor sam-
ples that might contain a mixture of tumor cells (papilloma
and SCC) as well as other nonkeratinocytes such as fibro-
blasts and endothelial cells. The classification of these
tumors into papilloma or SCCwas based on gross pathology,
which reflected the majority of the tumor cells in a given
sample but failed to take into account other tissue types
present in the samples. These factors contributed to the
variations in catalase message levels found in the tumors.
The results from the in vivo tumor progression experiment
recapitulated our previous observation that catalase was
downregulated at both mRNA and protein levels during
in vitro tumor progression [7].
Catalase expression is known to be regulated at multiple
levels, including the message, protein, and activity levels
[22,18]. Reports in the literature have shown that cells have
evolved different strategies to downregulate the expression
of catalase. In both mouse and rat hepatoma cells, catalase
is reported to be repressed at the transcriptional level
[23,17,21,24]. In neonatal rat lung and human breast cancer
cells, catalase expression is believed to be downregulated
by decreases in message stability [25,26]. Reimer et al. have
reported that the 3V untranslated region of mouse catalase
mRNAmight be used to regulate translation rates in a tissue-
specific manner during development [27]. In addition, the
acatalasemic mouse strain, Csb, was found to contain a
glutamine-to-histidine transversion mutation in the coding
region of catalase that rendered the protein unstable under
physiological conditions [28]. We have ruled out translational
repression as a possible mechanism in our system because,
in such a scenario, we would have expected the steady-state
mRNA levels of 308, 6M90, and 6R90 cells to be very similar.
Instead, 308 cells have approximately four-fold higher cata-
lase mRNA than 6M90 and 6R90 cells (Figure 4, 0 hour time
point). Southern blot analysis revealed that the catalase
genomic structures were identical between the three cell
lines. It indicated that no rearrangement or deletion had
taken place in the 6M90 or 6R90 cells that could account
for the reduction in steady-state mRNA levels. Next, we
examined the message half-life of catalase in these cell lines
using actinomycin D treatment. We failed to detect any
decreases in 6M90 and 6R90 message stability that would
lead to lower steady-state levels. In fact, we found that
messages in 6M90 and 6R90 cells were more stable than
those in 308 cells. The only other way to decrease steady-
state message levels would be a transcriptional repression in
the 6M90 and 6R90 cells. Results from the nuclear run-on
experiments provided strong evidence to support that theory.
The 6M90 and 6R90 cells’ rates of catalase transcription
were reduced in half compared to the 308 cells. We believe
that this was the mechanism that accounts for the reduction
in steady-state mRNA levels. To further dissect the mecha-
nisms behind the transcriptional repression, we examined
both genetic and epigenetic changes in the catalase promot-
er found in the 6M90 and 6R90 cells. Genomic sequencing
of the catalase promoter (557 to +89) did not reveal any
differences between the three cell lines. Sun et al. [21] have
shown in rat hepatoma cells that aberrant methylation in the
catalase promoter led to downregulation of transcription. We
failed to find any evidence for methylated CpG sites in the
Figure 5. Decreased catalase transcription rates in malignant variants.
Nuclear run-on assays were performed as described in Materials and Methods
section. The results shown here represent the average ± SD of three experi-
ments. To compare the differences between cell lines, the level of run-on catal-
ase message produced by the 308 cells was set as one in each experiment.
Table 1. Sodium Bisulfite Sequencing of the Catalase Promoter Regions in
308, 6M90, and 6R90 Cells.
Methylation Status of the Catalase Promoter
Methylated CpG/Total CpG Cell Line
308 0/17
6M90 0/17
6R90 0/17
Genomic DNA from the three cells lines were bisulfite-modified and subjected
to two rounds of nested PCR to amplify the 248 to +92 catalase promoter
region. Ten clones of each cell line were sequenced and analyzed for CpG
dinucleotide methylations.
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catalase promoter using bisulfite sequencing (Table 1) and
methylation-sensitive Southern blot analysis (data not
shown). It had recently been suggested by Georgel et al.
[29] that chromatin condensation and gene silencing by the
transcription repressor, MeCP2, could occur independent of
the DNA methylation status. We have tested this potential
explanation for catalase gene silencing by treating the three
cell lines with histone deacetylase inhibitor, trichostatin A,
but we failed to detect any change in the steady-state level of
catalase mRNA (data not shown). Because the mechanism
of action for trichostatin A is specific for histone deacetylase
and is DNA methylation– independent, we concluded that
MeCP2 or chromatin remodeling does not play an important
role in the silencing of catalase in the malignant cells.
Based on these findings, we believe that the attenuation
of catalase expression in the tumor cells is due to a dysre-
gulation of catalase promoter activity. The catalase promoter
in mice, rats, and humans have been documented to contain
multiple enhancer and silencer regions [12,16,17,30,31]. The
transcriptional repression observed in the malignant cells
can be the result of increases in silencer elements,
decreases in enhancer elements, or a combination of both.
Sato et al. [17] and Takeuchi et al. [30] discovered two
distinct silencer elements that were responsible for the
negative regulation of catalase transcription in rat hepatoma
cells. The silencer elements were located between 3.4 and
1.7 kb upstream of the rat catalase transcription start site.
They determined that nuclear proteins, which are abundantly
expressed in dedifferentiated hepatoma cells but scarcely
expressed in well-differentiated liver cells, bound specifically
to these silencer elements, leading to the downregulation of
transcription. Based on our results from the transactivation
reporter assays, we have determined that a potential silencer
element exists in the 1994 to 1694 region. However, this
silencer region does not seem to play a role in the differential
transcription rate between the 308, 6M90, and 6R90 cells.
The promoter region of the catalase gene shared a high
degree of homology between species (mouse [18], rat [32],
and human [33]). All three promoters lack TATA boxes but
contain binding sites for CCAAT box and GC box proteins. It
is likely that all three species share some common mecha-
nisms for transcriptional regulation of catalase. Nenoi et al.
had reported that hydrogen peroxide–resistant human leu-
kemia HP100 cells have constitutively elevated catalase
promoter activity. The promoter activity was reduced follow-
ing ionizing radiation exposure [16]. They concluded that the
interaction between multiple transcription factors in the176
to +16 promoter region in the human catalase gene was
Figure 6. Catalase promoter transactivation. (A) 308, 6M90, and 6R90 cells were transfected with a luciferase reporter construct driven by the catalase promoters
ranging in size from 2621/+68 to 191/+68. Luciferase assays were performed as described in Materials and Methods section. (B) Expression levels of WT1
protein in 308, 6M90, and 6R90 cells. Western blot analysis was performed with 20 g of total protein in each lane and probed with anti –WT1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). The blot was then stripped and reprobed with anti –-actin antibody (Sigma) for loading control. (C) Increase in catalase promoter
activity by abrogation of WT1 binding on the 191/+68 reporter construct. Results of the luciferase reporter assays shown are representative of three independent
experiments performed in triplicate ± SD.
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responsible for the regulation of catalase transcription in the
HP100 cells. These factors include SP1, NF-Y, and WT1.
The elevation of catalase transcription was the result of
elevated expression of SP1 and NF-Y in the HP100 cells.
They theorized that ionizing radiation induced the associa-
tion of WT1 to its response element and inhibited SP1
binding through steric hindrance. We speculate that a similar
mechanism is at work in our model system. The increased
expression of WT1 protein in our malignant cells could lead
to increased binding to the GC box, thus reducing the bind-
ing of SP1 to the same element, leading to the lost of
catalase promoter transactivation.
Our study has shown for the first time that catalase
expression is downregulated in the multistep mouse skin
carcinogenesis model in vivo. In the literature, MnSOD had
been reported as the major antioxidant enzyme involved in
the mouse skin carcinogenesis model by Zhao et al. [34].
That study focused on the role of MnSOD as a mediator of
ROS during the promotion step of carcinogenesis. The
results from our laboratory suggested that catalase plays
an important role as an antioxidant in maintaining the redox
state during the progression step of carcinogenesis. Further-
more, we were able to show that catalase repression oc-
curred at the transcriptional level in both chemical and
physical carcinogen-derived cell lines, thus highlighting its
potential role as a key tumor-suppressor gene in the etiology
of SCCs in general.
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